MedPath

Staten Biotechnology BV

Staten Biotechnology BV logo
🇳🇱Netherlands
Ownership
Holding
Established
2000-01-01
Employees
1
Market Cap
-
Website
https://www.statenbiotech.com

A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Phase 1
Terminated
Conditions
Hypertriglyceridemia
Interventions
Drug: Placebo
First Posted Date
2020-06-05
Last Posted Date
2023-01-23
Lead Sponsor
Staten Biotechnology BV
Target Recruit Count
93
Registration Number
NCT04419688
Locations
🇬🇧

Covance Leeds Clinical Research Unit, Leeds, West Yorkshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath